Affluent Medical SAS (AFME) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Affluent Medical SAS (AFME) has a cash flow conversion efficiency ratio of -0.319x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-6.74 Million ≈ $-7.88 Million USD) by net assets (€21.11 Million ≈ $24.68 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Affluent Medical SAS - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read AFME total debt and obligations for a breakdown of total debt and financial obligations.
Affluent Medical SAS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Affluent Medical SAS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Union Bankshares Inc
NASDAQ:UNB
|
0.125x |
|
NeoPharm CO. LTD
KQ:092730
|
0.031x |
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
N/A |
|
Borosil Scientific
NSE:BOROSCI
|
N/A |
|
Nova Klúbburinn hf.
IC:NOVA
|
N/A |
|
SAMYOUNG M-Tek Co. Ltd
KQ:054540
|
0.009x |
|
Nerdy Inc
NYSE:NRDY
|
-0.065x |
|
Se Gyung Hi Tech Co.Ltd
KQ:148150
|
0.105x |
Annual Cash Flow Conversion Efficiency for Affluent Medical SAS (2016–2024)
The table below shows the annual cash flow conversion efficiency of Affluent Medical SAS from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Affluent Medical SAS market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €30.27 Million ≈ $35.39 Million |
€-11.32 Million ≈ $-13.24 Million |
-0.374x | +2.33% |
| 2023-12-31 | €31.47 Million ≈ $36.79 Million |
€-12.05 Million ≈ $-14.09 Million |
-0.383x | -16.94% |
| 2022-12-31 | €33.83 Million ≈ $39.55 Million |
€-11.08 Million ≈ $-12.95 Million |
-0.328x | -15.33% |
| 2021-12-31 | €43.53 Million ≈ $50.90 Million |
€-12.36 Million ≈ $-14.45 Million |
-0.284x | -12.16% |
| 2020-12-31 | €35.29 Million ≈ $41.26 Million |
€-8.94 Million ≈ $-10.45 Million |
-0.253x | +35.66% |
| 2019-12-31 | €30.96 Million ≈ $36.20 Million |
€-12.19 Million ≈ $-14.25 Million |
-0.394x | -122.87% |
| 2017-12-31 | €61.39 Million ≈ $71.78 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.177x | +4.12% |
| 2016-12-31 | €58.87 Million ≈ $68.82 Million |
€-10.84 Million ≈ $-12.68 Million |
-0.184x | -- |
About Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more